A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
NCT ID: NCT00808418
Last Updated: 2014-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
34 participants
INTERVENTIONAL
2008-11-30
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00052845
Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
NCT00002721
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00004001
Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
NCT01378091
Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer
NCT00132756
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
Elesclomol Sodium
Chemotherapy agent
Docetaxel
Chemotherapy agent
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Elesclomol Sodium
Chemotherapy agent
Docetaxel
Chemotherapy agent
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No more than one prior chemotherapy on which the disease progressed
* ECOG performance status of less than or equal to 2
* Adequate bone marrow, renal and hepatic functions as defined in the protocol
* Neuropathy less than or equal to 2
* Reliable venous access for frequent study drug infusions
Exclusion Criteria
* Known active brain metastases
* Subjects that have received treatment for other malignancies with in the past 5 years
* Other clinically significant uncontrolled conditions
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Synta Pharmaceuticals Corp.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pacific Coast Hematology/Oncology Medical Group
Fountain Valley, California, United States
Mayo Clinic
Rochester, Maryland, United States
Mid Dakota Clinic
Bismarck, North Dakota, United States
University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development
San Antonio, Texas, United States
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4783-12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.